Literature DB >> 23133279

Primary mucormycosis of abdominal wall: A rare fungal infection in a immunocompetent patient.

Sahu Tapish1, Mustafa Taha, Garg Naresh, Dhamija Neeraj, K Malik Vinod.   

Abstract

Mucormycosis of the anterior abdominal wall is an uncommon disease and it is very rare to find this disease in immunocompetent, non-diabetic patients which usually affects patients with trauma, with contaminated wounds, patients with underlying malignancies or patients with immunocompromised state, e.g., diabetics. We herein report a case of primary cutaneous mucormycosis in an immunocompetent and non-diabetic patient. Our patient was a 48-year-old female, executive by profession. She was diagnosed to have cutaneous mucormycosis of the anterior abdominal wall, and was managed with multiple debridements of the wound and intravenous amphotericin B therapy. She was administered a total of 1500 mg of liposomal amphotericin B and when fully healed, split skin grafting was done. We would like to emphasize the importance of high index of suspicion and early start of therapy in a condition with high rate of mortality.

Entities:  

Keywords:  Abdominal wall; Immunocompetent; Mucormycosis

Year:  2010        PMID: 23133279      PMCID: PMC3451855          DOI: 10.1007/s12262-010-0080-x

Source DB:  PubMed          Journal:  Indian J Surg        ISSN: 0973-9793            Impact factor:   0.656


  9 in total

1.  Successful treatment of rhinocerebral zygomycosis using liposomal nystatin.

Authors:  L Mileshkin; M Slavin; J F Seymour; A McKenzie
Journal:  Leuk Lymphoma       Date:  2001 Sep-Oct

2.  Primary cutaneous mucormycosis in an immunocompetent host.

Authors:  Wani Tehmeena; Wajahat Hussain; Haroon R Zargar; Abdul Rashid Sheikh; Shabir Iqbal
Journal:  Mycopathologia       Date:  2007-08-04       Impact factor: 2.574

3.  Hospital-acquired mucormycosis (Rhizopus rhizopodiformis) of skin and subcutaneous tissue: epidemiology, mycology and treatment.

Authors:  G Gartenberg; E J Bottone; G T Keusch; I Weitzman
Journal:  N Engl J Med       Date:  1978-11-16       Impact factor: 91.245

4.  Cutaneous mucormycosis due to Absidia corymbifera occurring after bone marrow transplantation.

Authors:  K W Leong; B Crowley; B White; G M Crotty; D S O'Briain; C Keane; S R McCann
Journal:  Bone Marrow Transplant       Date:  1997-03       Impact factor: 5.483

Review 5.  Primary cutaneous mucormycosis in an immunocompetent host: report of a case.

Authors:  Arvind Kumar; Gopi C Khilnani; Sandeep Aggarwal; Subodh Kumar; Uma Banerjee; Immaculata Xess
Journal:  Surg Today       Date:  2003       Impact factor: 2.549

Review 6.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

Review 7.  Zygomycosis (mucormycosis): emerging clinical importance and new treatments.

Authors:  Richard N Greenberg; Lauren J Scott; Heather H Vaughn; Julie A Ribes
Journal:  Curr Opin Infect Dis       Date:  2004-12       Impact factor: 4.915

8.  Cutaneous mucormycosis in a heart transplant patient associated with a peripheral catheter.

Authors:  J Baraia; P Muñoz; J C Bernaldo de Quirós; E Bouza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-09       Impact factor: 3.267

9.  Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data.

Authors:  T T Ng; D W Denning
Journal:  Arch Intern Med       Date:  1995-05-22
  9 in total
  2 in total

Review 1.  Primary cutaneous zygomycosis in India.

Authors:  Robin Kaushik
Journal:  Indian J Surg       Date:  2012-03-20       Impact factor: 0.656

Review 2.  Posttraumatic mucormycosis: a nationwide study in France and review of the literature.

Authors:  Lucie Lelievre; Dea Garcia-Hermoso; Hendy Abdoul; Mickael Hivelin; Taieb Chouaki; Dominique Toubas; Anne-Claire Mamez; Laurent Lantieri; Olivier Lortholary; Fanny Lanternier
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.